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with that observed with warfarin therapy
Background. It has ban reported that combined warfarin and
an a telet therapy may be effective but may associated with
an i he c risk. Therefore, definite benefits of the
treatment in patients with Implanted prosthetic valve have not
dearly documented .
elhod. Between Jan 1 and December 1992, 195
patients with a St . Jude Medical valve at the mi (plus aortic)
position were eO to receive treatment with either warfa
Wone (125 patients) or wars plus and platelet agents (70
patients), such as dipyrid ole (150 or 300 mg daily, 14 patients)
or Idine ( or 400 mg daily, S6 patients). A min dose
of aspirin (10 to 40 mg) was added (29 patients) if the maximal
platelet Lion rate by collagen was not reduced . The target
th botest level was 10% to 20% .
It is well recognized that patients with mechanical valve
replacement are at increased risk for stroke and that anti-
coagulant therapy using warfarin sodium Coumadin has been
successful in reducing the incidence of stroke (1-3) . Despite
a strict anticoagulant regimen, the reported incidence of
cerebral embolism was 0 .5% to 4.3%/patient-year in patients
with a St. Jude Medical valve (1-3). Some investigators have
reported that a less intensive warfarin regimen reduced the
hemorrhagic risk during anticoagulant therapy (4,5). Con-
versely, Ribeiro et al . (6) reported a low thromboembolic
complication rate in patients with an aortic St. Jude Medical
valve when antiplatelet agents only were given (6). Some
antiplatelet agents, such as aspirin, ticlopidine hydrochloride
and dipyridamole have been used not only in cardiovascular
surgery but also for prevention of the recurrence of cerebral
infarction (7-9) .
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Results . The two treatment groups were similar with regard to
gender and age distribution . The number of patients with atrial
fibrillation, left atrial thrombus, history of previous stroke, simul-
taneous aortic valve operation and previously performed valve
procedures were comparable in the two groups. Actuarial survival
te at 10 years was 98.3 ± 1 .7% (mean ± SD) in the warfarin
us antiplatelet group and 90.3 ± 3.2% in the warfarin group
(p < 0 .05 at 1 and 9 to 12 years). The actuarial stroke-free rate at
years was 95.3 dA 3.4% and 84.3 ± 3.8%, respectively (p <
0.05 by the general Wilcoxon test). The actuarial complica-
tion-free rate at 10 years was 89.4 ± 4.3% and 67 .9 ± 4.8%,
respectively (p < 0.05 by the generalized Wilcoxon test). No
hemorrh is complications were seen in the warfarin plus anti-
platelet group.
Conclusions . The results strongly indicate the effectiveness and
safety of combined w arin plus antipiatelet treatment after St .
Jude Medical valve replacement for mitral (plus aortic) valve
disease.
(J Am Coll Cardiol 1994;23:672-7)
Trials of the combined warfarin plus antiplatelet therapy
have reported effective results in patients with prosthetic
valves (10,11). Chesebro et al . (10) reported a lower inci-
dence of thromboembolism and bleeding using the warfarin
plus dipyridamole therapy in patients who received Starr-
Edwards or Bj®rk-Shiley valves (10), but another report (12)
concerning prosthetic valves described other morbidity that
might be affected by blood coagulability . The present study
was designed to clarify whether warfarin plus antiplatelet
therapy could reduce fatal or nonfatal morbidity compared
with that observed with warfarin therapy alone .
Methods
Patients. Between January 1980 and December 1992, 195
patients receiving a St. Jude Medical heart valve at the mitral
position (including a simultaneous aortic valve replacement
using the St. Jude Medical valve) were allocated to receive
treatment with either warfarin alone (125 patients) or war-
farin plus antiplatelet agents (70 patients) in nonrandomized
manner. Selection of treatment was left to the attending
physicians, who were informed that either treatment was
allowed . Patients who received another prosthetic valve in
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O rives . The clinical effect of combined warfarin and anti-
pla therapy on the incidence of stroke and postoperative
alter mi (plus aortic) valve replacement was
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combination with the St . Jude Medical valve and I I patients
(5.3%) who died during the hospital period of various causes
were excluded from the present study .
Forty-six of the 195 study patients (76 male, 119 female ;
mean age (tSD1 49 ± 12 years [range 6 to 73)) . had
undergone 54 previous valve procedures, including 17 pros-
thetic valve replacements and 4 emergency operations for
intractable active endocarditis, thrombosed disc valve or
severe left ventricular dysfunction .
Preoperative coronary anjog,raphic evaluation was per-
formed in all but 13 patients, who required emergency
operation or were < 15 years of age . Coronary artery disease
was defined as >50% lumen narrowing in at least one
coronary artery . Cineventriculography was performed in all
patients except those who had active infective endocarditis
or were undergoing emergency operation . Left ventricular
ejection fraction was calculated from end-diastolic and end-
systolic volumes measured according to the Dodge area-
length method (13) .
We used a Bentley or Maxima oxygenator during cardio-
pulmonary bypass and maintained moderate hypothermia
during aortic cross-clamping. In 1984, we introduced the use
of a cold St. Thomas Hospital solution instead of cold
glucose-insulin-potassium solution to protect the myocar-
dium during cardiac arrest, and since February 1987 we have
used the former exclusively . The posterior mitral leaflet
preservation technique was used in only a small number of
patients before December 1985 but has since been regularly
applied except in patients with prosthetic valve failure or a
small mitral annulus. Since 1982, we have oriented the mitral
valve perpendicular to the natural leaflet . Before 1982 we
used parallel orientation .
Anticoagulant therapy and follow-up. Anticoagulant and
antiplatelet therapy were started on postoperative day I or 3 .
The daily dose of warfarin was based on the thrombotest
level, which reflects the anticoagulation activity of Factors
II, VII and X and protein induced by vitamin K antagonists
(14) and was measured every 3 days during the hospital
period and every 2 to 4 weeks after hospital discharge . The
target thrombotest level was 10% to 20% . To inhibit platelet
aggregation, since 1984 we have used ticlopidine (100 or
200 mg twice a day) instead of dipyridamole (150 or
300 mg/day in two or threee divided portions) . A minimal dose
of aspirin (range 10 to 40 mg/day) was added if a maximal
aggregation rate of platelet by collagen was not suppressed .
The daily dose of antiplatelet agents was based on the
maximal aggregation rate (15), which was measured every 6
months. If a patient manifested nausea, leukopenia, liver
injury and other complications due to antiplatelet therapy,
this therapy was discontinued .
Follow-up was completed in February 1993, and the
following details were checked : cerebrovascular stroke,
thromboembolic event in peripheral arteries, hemorrhage
that necessitated blood transfusion, prosthetic valve endo-
carditis, structural or nonstructural deterioration of the
prosthetic valve, myocardial infarction, malignant disease,
Table 1
. Baseline Characteristics*
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surgery
Follow-up duration
(patient-ye)
*Factors that affect postoperative outcome were comparable between the
two groups . tUnpaired
f test . Unless otherwise indicated, values presented
are number (%) of patients . A F = atrial fibrillation
; AP = antiplatelet agents ;
AVR aortic valve replacement
; LA thrombus = left atria] thrombus ;
MVR mitral valve replacement
.
reoperation and death . Definitions of mortality and morbid-
ity followed the guidelines of Edmunds et al . (16) . Cerebral
infarction due to thromboembolism was defined as a neuro-
logic deficit of sudden onset with evidence of a low density
area by brain computed tomography or arterial occlusion
documented by angiography .
If a neurologic deficit disappeared within 24 h, the patient
was considered to have had a transient ischernic attack
unless a high density area was rioted on computed tomogra-
phy. Follow-up ranged from 2 months to 13 years (average
6.5 ± 3 .9) . No patient was lost to follow-up .
Statistical analysis . Comparison of variables between the
two groups was by the unpaired i test . Incidence was
compared by chi-square analysis . Survival and stroke- and
complication-free curves were constructed by Kaplan-Meier
actuarial methods . Actuarial rates are presented as mean
value ± I SEM, and the difference between the two groups
was tested for significance by the generalized Wilcoxon test .
Results
Patient characteristics . Table I lists the baseline charac-
teristics of the two groups at the time of operation . The two
groups were similar with regard to gender and age distribu-
tion . Factors that may affect postoperative outcome, such as
cardiac rhythm, left atrial thrombus, history of previous
stroke, simultaneous aortic valve operation and previous
valve procedures, were comparable between the two groups .
The cumulative follow-up period was 845 patient-years in the
warfarin group and 404 patient-years in the warfarin plus
antiplatelet group . Of 70 patients in the warfarin plus anti-
platelet group, 14 received dipyridamole and 56 ticlopidine .
Aspirin was added in 29 patients on the basis of the maximal
aggregation rate of platelet by collagen .
845 404
Warfarin
Group
(a = 125)
Warfarin + AP
Group
(n = 70)
p Value
(chi-square test)
M1F 51174 2545 NS
Age tyr)
Range 7 to 73 6 to 67
Mean ± SD 49.2 ± us 49 .8 ± 11 .3 NSf
AF 95(76) 59(84) NS
LA thrombus 16(13) 14(20) NS
Previous stroke 29 (23) 17 (24) NS
AVR + MVR 20(16) 14(20) NS
Previous valve 25 (20) 21(30) NS
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Table 2. Baseline Cardiac Status and Intraoperative
Characteristics
*Chi-square test . Values presented are number of patients. AP = anti-
platelet agents ; GIK = cold glucose-insulin-potassium solution ; LVEF = left
ventricular ejection fraction determined by preoperative cardiac catheteriza-
tion
; PML
= posterior mitral leaflet ; St . Thomas = cold St. Thomas Hospital
solution .
Table 2 lists preoperative cardiac status and the number
of patients who received each cardioplegic solution and
mitral leaflet preservation technique . The type of mitral
lesion, incidence of abnormal coronary anatomy and left
ventricular ejection fraction were comparable between the
two groups . The St. Thomas Hospital solution was used
more frequently in the warfarin plus antiplatelet group
compared with the warfarin group (p < 0.01). However,
there were no significant differences between the group that
received the St . Thomas Hospital solution (95 patients) and
those that received the glucose-insulin-potassium solution
(100 patients) with regard to actuarial survival rate (at
8 years, 94.2 ± 3.6% vs . 93.5 ± 2 .6%), actuarial stroke-
free rate (at 8 years, 89 .7 ± 5.5% vs. 87.5 ± 3.4%) and
actuarial complication-free rate (at 8 years, 69 .8 ± 8.2% vs .
77,1 ± 4 .2%).
In the warfarin plus antiplatelet group, the posterior
mitrall leaflet preservation technique was used in the majority
of patients (p < 0 .01 compared with patients in the warfarin
group. There were no significant differences between the
groups treated with (86 patients) and without (109 patients)
the technique in terms of actuarial survival rate (at 10 years,
91 .1 ± 4.2% vs. 94.3 ± 2.5%), actuarial stroke-free rate (at
10 years, 85.3 ± 7.4% vs. 88.0 ± 3.3%) and actuarial
complication-free rate (at 10 years, 64
.4 ± 9.1% vs. 78 .1
4.2%) .
Table 3 . Causes of Late Death
Stroke
Peripheral embolism
PVE
Sudden death
Cardiac failure
Malignancy
Infection
Total
1 .0
0.7
1:;R
W + AP therapy
W therapy
JACC Vol, 23, No
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Warfarin Group Warfarin + AP Group
Values presented are number of patients, AP = antiplatelet agents ; pts
patients ; PVE = prosthetic valve enduarditis .
Actuarial survival and causes of late death. Of 125 pa-
tients in the warfarin group, 12 patients died late postoper-
atively of a wide variety of causes (Table 3), whereas only
I patient died of a sudden unknown cause in the warfarin
plus antiplatelet group . No patient in either group died of
stroke. The postoperative actuarial survival rate at 5 and 10
years was 98 .3 t 1 .7% at both dates in the warfarin plus
antiplatelet group and 93 .4 ± 2.4% and 90.3 ± 3.2% .
respectively, in the warfarin group (Fig . 1). There was a
significant difference between the two groups at 1 year and at
10 to 12 years (p < 0.05), No significant difference was
observed between the two survival curves by the generalized
Wilcoxon test .
Cerebrovascular strokes and stroke-free rate . Cerebral
infarction and transient ischernic attack occurred in six
patients, respectively, in the warfarin group. However, only
two patients experienced cerebral infarction in the warfarin
Figure 1
. Actuarial survival rate in the patients receiving warfarin
(W) plus antiplatelet (AP) therapy and in those receiving warfarin
therapy alone after St . Jude Medical mitral valve replacement (Ope) .
A significant difference was observed between the two groups at 1,
9,10 (p < 0,05) and 2:11 years postoperatively (p < 0.01) . However,
the generalized Wilcoxon test revealed no significant difference
between the two survival curves
.
Warfarin Group
(n = 125)
Warfarin + AP Group
(n = 70)
p Value*
Mitral lesion
Stenosis
51 25
Stenosis plus
25 10
regurgilotion
Regurgitation
36 31
NS
Prosthetic failure
13 4
cooromnowy arteries
Norm l 108 63
Disaa present
7
4 NS
Undetermined
t0 3
LVEF
50 22
to 59% 54 29
40% to 49% IS
17
NS
=9%
3 2
Cardiqlegia
UK 73 27
< 0.01
St . Thomas 52
43
PAIL preservation
Yes 43
43
< 0.01
No 82 27
n W+APtherapy (n=70)
• W therapy (n
.125)
*
*2
p<0.05
P<0 .01
1-- _5156o
10
13years
0 no 70 68 63 54 48
after operation
5 236 31 19 16 13 8
a n=125108101 96
90 85 84 80 65 56 39 27 16 3
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Table 4. Cerebrovascular Strokes
plus antiplatelet group (Table 4) . These two patients had
basilar artery occlusion and received direct thrombolytic
revascularization using urokinase or tissue plasminogen ac-
tivator through a microcatheter placed in the basilar artery .
Details have been reported elsewhere (17) . One patient had
a subcortical hemorrhage during prosthetic valve endocardi-
tis, and one patient with long-term hemodialysis had a
subdural hematoma . No patient had intracranial hemorrhage
in the warfarin plus antiplatelet group . The actuarial stroke-
free rate at 5 and 10 years was 98 .4 ± 1 .6% and 95 .3 ± 3.4%,
respectively, in the warfarin plus antiplatelet group and
89.3 ± 3.1% and 84.3 ± 3 .8% in the warfarin group (Fig . 2) .
Significant intergroup difference was confirmed by the gen-
eralized Wilcoxon test (p < 0.05) .
Late postoperative complications and complication-fired
rate. Table 5 summarizes the late postoperative comnhca-
tions, including strokes and death from various cazses . The
proportion of cardiac or valve-related deaths and myocardial
infarction was higher in the w,,varfarin group than in the
warfarin plus antiplatelet group . The cause of reoperation
was hemolytic anemia in three patients, paravalvular leakage
in one patient and idiopathic intestinal hemorrhage in one .
Figure 2. Actuarial stroke-free rate in the two study groups
. There
was a significant intergroup difference confirmed by the generalized
Wilcoxon test (p < 0.05). Abbreviations as in Figure I .
1 .0
a)
20.9
20
.8
U)
* W + AP therapy (n=70) ~p<0-05
* W therapy
	
(n=125) I
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Table S . Late Postoperative Complications
0.
E
0
0 0 .7
1 .01
Z
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'in the warfarin group, stroke occurred in two patients during the
treatment of prosthetic valve endocarditis (PVE) (one patient) and malignant
disease (one patient), and one patient died of septic shock 2 years after stroke
.
AP = antiplatelet agents
.
The first four of these patients had received a Bj6rk-Shiley
prosthetic valve and the latter a Carpentier-Edwards porcine
valve at the time of reoperation . Of the five patients with a
myocardial infarction, coronary angiographic findings in two
patients showed a progression of stenotic lesions compared
with the preoperative lesion, whereas in three other patients
preoperative coronary angiography showed normal findings .
The actuarial complication-free rate, including all compli-
cations listed in Table 5, at 5 and 10 years was 92 .4 ± 33q%
and 89.4 ± 4.3%, respectively, in the warfarin plus antiplate-
!et group, and 77 .5 ± 4.0% and 67 .9 ± 4.8%, respectively, in
the warfarin group (Fig . 3) . Significant intergroup difference
was confirmed by the generalized Wilcoxon test (p < 0.05) .
Discussiomn
Warfarin is known to interfere with the coagulation
cascade in the activation of Factors 11, VII, IX and X ;
Figure 3. Actuarial complication-free rate in the two study
groups .
There was a significant intergroup difference confirmed by the
generalized Wilcoxon test (p < 0.05) . Abbreviations as in Figure 1
.
* W + AP therapy (n=70)
I
p<015
* W therapy (n=125)
Warfarin Group Warfafin + AP Group
Cerebral infarct 6
2
TIA 6 0
Subarachnoid H 0 0
Subcortical H 1 0
Subdural H 1 0
Total 14 2
Values presented are number of patients . AP = antiplatelet agents ; H
hemorrhage or hematoma . TIA = transient ischernic attack .
Warfarin Group
-arfa6n + AP Group
Stroke 14
2
Peripheral emboli
1 0
I'VE
2 *
l
Cardiac or valve-related death
7 1
Myocardial infarction 5
0
1
operation 3 0
Malignancy 6
2
Infection 2
0
Total 40
6
L___-A I I
I
I .
Ope 1 5
after operation
10 1 3years
after operation
0 n= 70 68 63 54 48 36 30 19 16 13 8 5 2
0 n= 70 67 60 52 45 35
29 19 16 13 8 5
2
0 n=125 104 96 89 81 77 74 70 58 50 36 27 16 3
E n=125 102 95 88 79 74 71 65 54 47 34
25 15 3
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therefore, it is considered to be the most effective drug for
reducing intravascular thrombogenesis. However, the pri-
mary thrombogenic mechanism starts from the adhesion and
aggregation of platelets with endothelium mediated by the
von Willebrand factor and fibrinogen (18) . For these rea-
sons, combined anticoagulant therapy using warfarin plus
antiplatelet agents may be more effective than either
therapy alone . Platelets are activated by both adenosine
diphosphate-mediated and cyclooxygenase-mediated activa-
tion mechanisms . In general, dipyridamole exerts a mild
blocking action on both activation mechanisms, whereas
ticlopidine blocks only the former, and a low dose of aspirin
(10 to 80 mmg) interferes exclusively with cyclooxygenase .
The characteristics of each drug help to modulate platelet
aggregation activity . If a target control level of maximal
gallon rate ( to by adenosine diphosphate (10
pmol] 3 to S0% by collagen [2 pg/mll) cannot be
achieved, then the daily dose of antiplatelet ents is varied
depending on the maximal aggregation rate of platelet by
each nist.
Survival rate. Although some multicenter trials using
antiplatelet agents demonstrated a significant reduction in
cardiac mortality in patients with unstable angina (19,20),
few reports have confirmed an improvement in postopera-
tive survival rate after prosthetic valve replacement . Com-
pared with previous reports in the United States (2,4,5), the
actuarial survival rate in both groups was higher, probably
owning to the younger patients and lower incidence of
complicated coronary artery disease in the present series .
One important finding in the present study is the higher
survival rate obtained in the warfarin plus antiplatelet group .
The warfarin group includes four patients who died suddenly
of unknown causes . In a randomized trial, Turpie et at . (12)
reported that in patients with valve replacement, vascular
death, including sudden death from unknown causes and
myocardial infarction, occurred less frequently in the war-
farin plus antiplatelet treatment group than in the warfarin
plus placebo treatment group (12) . Davies et al . (21) related
the effect of platelet aggregation in intramyocardial artery to
sudden cardiac death in patients with unstable angina . How-
ever, no reports have described what role platelet aggrega-
tion activity plays in hypertrophied cardiac muscle . Further
investigation is needed to clarify the relation between coag-
ulability and ventricular arrhythmias .
H e . At the beginning of the study,
we thought that hemorrhagic risk might increase in the
warfarin plus antiplatelet group, which is probably why
relatively fewer patients received the combined treatment .
Fortunately, no intracranial or other major hemorrh e
occurred, although a slightly increased rate of subcutaneous
hemorrhage was observed .
The principal finding of the present study is that the
incidence of cerebrovascular stroke, including hemorrhage,
was significantly reduced in the warfarin plus antiplatelet
group (0
.5%/patient-year) compared with 1 .7%/patient-year
in the warfarin group, which was similar to previous reports
JACC Vol . 23 . No
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with warfarin (1- .3) . This success is considered to be attrib-
uted to a strict anticoagulant regimen and safely controlled
platelet aggregation activity . Chesebro et aL (10) emphasized
the danger of aspirin compared with dipyridamole in combi-
nation with warfarin (10). Compared with the moderate dose
of aspirin (500 mg/day) used in their study, our patients
received 10 to 40 mg/day of aspirin on the basis of measured
platelet aggregation activity . In the study of Turpie et al.
(12), the daily dose of aspirin was fixed at 100 mg because
of the potential increased risk for hemorrhage with doses of
>100 mg/day. Balsano et al . (9) reported the efficacy of
ticlopidine treatment over aspirin therapy, although some
adverse reactions were seen . In the present study, two
patients had neutropenia and skin eruption, respectively,
and required discontinuation of ticlopidine treatment during
the hospital period . However, no patient in the warfarin plus
antiplatelet group required blood transfusion because of
massive hemorrhage . We believe that the lower incidence of
hemorrhage in the present series is due to the lower, more
appropriate dose of antiplatelet agent and a less intensive
warfarin treatment regimen (a thrombotest level 10% to 20%
is equivalent to prothrombin time [international normalized
ratio] of 1 .8 to 2.8) .
Other nonfatal morbidity. The remarkable reduction in
the incidence of postoperative complications in the warfarin
plus 3ntiplatelet group (Table 5) in the present study oc-
curred mainly because stroke, cardiac or valve-related death
and myocardial infarction were less common . Many inves-
tigators have reported successful prevention of graft occlu-
sion (8) and a protective effect against myocardial infarction
(12,19,20) by antiplatelet agents . These achievements sup-
port the results in the present study. Another reason for our
high success rate might be an inclusion of fewer patients with
complicated coronary artery disease than those included in
previous studies (1-3) .
Conclusions. A higher survival rate, lower incidence of
cerebrovascular strokes and better quality of life with fewer
postoperative complications were obtained with the com-
bined warfarin plus antiplatelet therapy after St . Jude Med-
ical valve replacement for mitral (plus aortic) valve disease .
The present study confirms that it is time to reconsider the
advantages of combined warfarin plus antiplatelet treatment
after mechanical valve replacement .
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